Purpose-built for physicians Semaglutide linked to reduced risk for Alzheimers in patients with diabetes Key takeaways: Semaglutide was associated with a 40% to 70% lower risk for AD diagnosis within 3 years vs
GLP-1 injections can have a similar impact for people who historically struggle to maintain a healthy relationship with food
Ten to twelve years is a relatively short period of time to study the long-term effects of a new class of drugs
If symptoms suggest a new endocrine problem, baseline testing is reasonable before starting therapy, with a follow-up check at three months for the standard panels: HbA1c, fasting glucose, TSH, and free T4 if on thyroid therapy, morning cortisol only when clinically indicated, and sex hormones if symptoms arise
While not all of these uses are proven (and some may never be), the fact that semaglutide is being investigated for so many different conditions is very exciting, especially for those with PMOS